Bayer’s heart failure drug bound for NHS on NICE recommendation
Kerendia will become available to English patients with chronic heart failure with preserved or mildly reduced ejection fraction.
Therapy Area
Women’s health attracted record equity in 2025 as companies share capital
EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients
Sanofi aims for Nexviazyme approval in younger Pompe disease patients
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
EHA26: Epcoritamab improves PFS but not OS in R/R LBCL
ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
